Targeting endothelial connexin40 inhibits tumor growth by reducing angiogenesis and improving vessel perfusion.
Fiche du document
22 mars 2016
- doi: 10.18632/oncotarget.7370
- issn: 1949-2553
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.18632/oncotarget.7370
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/26883111
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1949-2553
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_42D2A26962721
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Mouse House mice Mus musculus House mouseCiter ce document
F. Alonso et al., « Targeting endothelial connexin40 inhibits tumor growth by reducing angiogenesis and improving vessel perfusion. », Serveur académique Lausannois, ID : 10.18632/oncotarget.7370
Métriques
Partage / Export
Résumé
Endothelial connexin40 (Cx40) contributes to regulate the structure and function of vessels. We have examined whether the protein also modulates the altered growth of vessels in tumor models established in control mice (WT), mice lacking Cx40 (Cx40-/-), and mice expressing the protein solely in endothelial cells (Tie2-Cx40). Tumoral angiogenesis and growth were reduced, whereas vessel perfusion, smooth muscle cell (SMC) coverage and animal survival were increased in Cx40-/- but not Tie2-Cx40 mice, revealing a critical involvement of endothelial Cx40 in transformed tissues independently of the hypertensive status of Cx40-/- mice. As a result, Cx40-/- mice bearing tumors survived significantly longer than corresponding controls, including after a cytotoxic administration. Comparable observations were made in WT mice injected with a peptide targeting Cx40, supporting the Cx40 involvement. This involvement was further confirmed in the absence of Cx40 or by peptide-inhibition of this connexin in aorta-sprouting, matrigel plug and SMC migration assays, and associated with a decreased expression of the phosphorylated form of endothelial nitric oxide synthase. The data identify Cx40 as a potential novel target in cancer treatment.